Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.09 USD

28.09
46,845,401

-0.21 (-0.74%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $28.11 +0.02 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (58 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

SpringWorks (SWTX) & AbbVie Unite for Multiple Myeloma Drug

SpringWorks Therapeutics (SWTX) collaborates with AbbVie (ABBV) to evaluate the combination of nirogacestat with AbbVie's ABBV-383 for relapsed or refractory multiple myeloma.

Pfizer (PFE) Gets Approval for New Eczema Drug in Europe

Pfizer's (PFE) oral JAK inhibitor, Cibinqo, gets approval for treating atopic dermatitis in adults who are candidates for systemic therapy in Europe.

Pfizer, BioNTech Booster Gets FDA Nod for 16- & 17-Year Olds

FDA authorizes the booster shot of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine for 16- and 17-year olds.

J&J's (JNJ) COVID-19 Booster Jab Gets WHO Recommendation

An advisory group of the World Health Organization recommends the booster dose of J&J's (JNJ) COVID-19 vaccine for use in adults.

Kinjel Shah headshot

Pharma Stock Roundup: PFE Booster Works on Omicron, AZN COVID Cocktail Gets FDA Nod

Pfizer (PFE) and BioNTech's COVID-19 booster shot proves effective against the Omicron variant. FDA grants EUA to AstraZeneca's (AZN) cocktail antibody for pre-exposure prophylaxis (prevention) of COVID-19.

Sweta Jaiswal, FRM headshot

ETFs to Play the Reopening Trade as Omicron Fear Subsides

The improved market sentiments have been leading to greater attention and confidence in reopening trades.

Pfizer (PFE) COVID-19 Booster Gives Protection Against Omicron

Pfizer (PFE) and BioNTech announce lab test data that demonstrates that the three doses of their COVID-19 vaccine provide significant protection against the Omicron variant.

Stock Market News for Dec 9, 2021

U.S. stocks closed slightly higher on Wednesday, with major indexes hovering around their record highs, as reports suggested that the Omicron variant of the coronavirus looks less dangerous that it was earlier thought.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

Pfizer (PFE) closed at $51.40 in the latest trading session, marking a -0.62% move from the prior day.

Markets Upbeat on Vaccine Efficacy Against Omicron Variant

Markets Upbeat on Vaccine Efficacy Against Omicron Variant

Mark Vickery headshot

Remedies for Omicron Apparent, Markets Up Again

New forms of Covid-19 appear to be growing more highly infectious, if not necessarily more life-threatening.

Is Principal U.S. MegaCap ETF (USMC) a Strong ETF Right Now?

Smart Beta ETF report for USMC

AbbVie's (ABBV) Rinvoq Meets Goals in Crohn's Disease Study

AbbVie's (ABBV) Rinvoq achieves primary and key secondary endpoints in the first phase III induction study in patients with Crohn's Disease.

Biohaven (BHVN) Intranasal Migraine Therapy Meets Goal in Study

Biohaven's (BHVN) pivotal study evaluating intranasal zavegepant for the acute treatment of migraine in adults meets co-primary endpoints. An NDA for zavegepant is expected to be filed in first-quarter 2022.

Funko, Bloomin' Brands, Johnson & Johnson, Pfizer and BioNTech highlighted as Zacks Bull and Bear of the Day

Funko, Bloomin' Brands, Johnson & Johnson, Pfizer and BioNTech highlighted as Zacks Bull and Bear of the Day

Kinjel Shah headshot

Vaccine Stocks Down as Omicron May Not Be Too Severe

Stocks of Moderna (MRNA), BioNTech (BNTX), Novavax (NVAX) and Pfizer (PFE) decline as data suggests that Omicron variant may cause less severe cases of COVID-19.

J&J (JNJ) COVID-19 Booster Jab Compares Well With Comirnaty

Booster dose of J&J's (JNJ) COVID-19 vaccine elicits comparable neutralizing activity and higher T-cell responses in previously-vaccinated persons with Comirnaty.

AbbVie (ABBV) Adds FDA-Issued New Warnings to Rinvoq's Label

AbbVie (ABBV) adds a heart-risk warning on the label of JAK inhibitor medicine, Rinvoq.

The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, J&J and Regeneron

The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, J&J and Regeneron

Kinjel Shah headshot

COVID-19 Vaccine & Drug Makers Gear Up to Fight Omicron

The Omicron variant ignites fears that currently available COVID-19 vaccines and treatments could be less effective against it. MRNA, PFE, BNTX, REGN and JNJ are some of the industry players gearing up to fight against this new variant.

Pfizer (PFE) Up 22% Since Last Earnings Report: Can It Continue?

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Merck (MRK) Vaxneuvance sBLA for Pediatrics Gets Priority Review

Merck (MRK) is seeking label expansion for Vaxneuvance for use in pediatric patients aged six weeks through 17 years for the prevention of invasive pneumococcal disease. A decision is expected by on Apr 1, 2022.

Merck (MRK) Up as COVID Pill Gets FDA Panel's Positive Vote

An FDA committee voted 13-0 to recommend authorization of Merck's (MRK) antiviral pill to treat COVID-19.

Moderna's (MRNA) Stock Falls on Omicron Variant Concerns

Moderna (MRNA) shares decline following a two-day rise as the Omicron-variant creates uncertainty with limited data. The next couple of weeks may provide a clearer picture.

The Zacks Analyst Blog Highlights: Mastercard, Pfizer, Nike, Lockheed Martin and Micron Tech

The Zacks Analyst Blog Highlights: Mastercard, Pfizer, Nike, Lockheed Martin and Micron Tech